Heart failure is a systemic disease in which neuroendocrine activation, inflammation and metabolic changes can impair cardiac function. In addition, variants in genes encoding sarcomeric proteins can predispose individuals to develop heart failure. The 2022 Gordon Research Conference on Cardiac Regulatory Mechanisms aims to identify novel treatment targets by applying high-resolution approaches to complex cardiac disorders.
References
Lehman, S. J., Crocini, C. & Leinwand, L. A. Targeting the sarcomere in inherited cardiomyopathies. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00682-0 (2022).
Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351–356 (2019).
Robertson, J. et al. Higher body mass index in adolescence predicts cardiomyopathy risk in midlife. Circulation 140, 117–125 (2019).
Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761–772 (2020).
Paulus, W. J. & Zile, M. R. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ. Res. 128, 1451–1467 (2021).
Wong, A., Hamidzada, H. & Epelman, S. A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00701-0 (2022).
Carnevale, D. Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00678-w (2022).
Caporizzo, M. A. & Prosser, B. L. The microtubule cytoskeleton in cardiac mechanics and heart failure. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00692-y (2022).
Karlstaedt, A., Moslehi, J. & de Boer, R. A. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-022-00698-6 (2022).
Meijers, W. C. et al. Heart failure stimulates tumor growth by circulating factors. Circulation 138, 678–691 (2018).
Acknowledgements
C.M. is funded by the German Research Foundation (DFG; Ma 2528/7-1; SFB 894, SFB 1525), the Barth Syndrome Foundation and the Corona Foundation. J.C.T. is funded by the NIH (HL075619, HL107046 and 137375) and the Steven M. Gootter Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.M. received honoraria as a speaker or consultant from Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Pfizer and Servier. J.C.T. received honoraria as a speaker or consultant from Bristol Myers Squibb, Cytokenetics and MyoKardia.
Rights and permissions
About this article
Cite this article
Maack, C., Tardiff, J.C. Targeted therapies for cardiac diseases. Nat Rev Cardiol 19, 343–344 (2022). https://doi.org/10.1038/s41569-022-00704-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-022-00704-x
- Springer Nature Limited
This article is cited by
-
Schnittstellen in der kardiovaskulären Medizin
Herz (2024)